Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
| Status: | Terminated |
|---|---|
| Conditions: | Hematology, Benign Prostate Hyperplasia, Urology |
| Therapuetic Areas: | Hematology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | December 2013 |
| End Date: | January 3, 2017 |
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study
The purpose of this observational study is to evaluate the outcomes of using the PlasmaButton
electrode in the treatment on Benign Prostatic Hyperplasia (BPH) while on anticoagulation
medication.
electrode in the treatment on Benign Prostatic Hyperplasia (BPH) while on anticoagulation
medication.
Inclusion Criteria:
- Men with obstructive symptoms due to benign prostatic hyperplasia who are also on
anticoagulant regimen.
- Anticoagulant regiments include: Aspirin 81mg, Aspirin 325mg, Adenosine diphosphate
(ADP) receptor inhibitors, Cilostazol, Dabigatran, Dipyridamole, or Warfarin. The
patient will be stable on their dosage regimen for at least 3 months.
- Maximum flow rate <15ml/s by uroflowmetry.
- International Prostate Symptom Score (IPSS)≥10.
Exclusion Criteria:
- Patients with coagulopathy, INR exceeding 3.
- Anti-coagulation dose changes within 3 months of surgery.
- Patients not medically cleared to undergo surgery for medical reasons.
- Patients with neurogenic bladder (bladder affected due to a neurologic cause).
- Urethral stricture, obstruction due to stricture.
- Suspected bladder or prostate cancer.
- Prostate size greater than 80 cc.
We found this trial at
2
sites
Los Angeles, California 90073
Principal Investigator: Carol J Bennett, MD
Click here to add this to my saved trials
Loma Linda, California 92354
Principal Investigator: Edmund Ko, MD.
Click here to add this to my saved trials